Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLLLina van der Straten, Mark‐David Levin, Ludo M. Evers et al.|Blood|2023Cited by 27
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLLPaul J. Hengeveld, Anton W. Langerak, P. Martijn Kolijn et al.|HemaSphere|2023Cited by 5
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLLLavinia Arseni, Martina Seiffert, Gianluca Sigismondo et al.|Nature Communications|2025Cited by 5
High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic LeukemiaPaul J. Hengeveld, Mark‐David Levin, P. Martijn Kolijn et al.|Blood|2022Cited by 0